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In this Review we provide a broad overview on the use of nanotechnology for the fight against breast 
cancer (BC). Nowadays, detection, diagnosis, treatment, and prevention may be possible thanks to 
the application of nanotechnology to the clinical practice. Taking into consideration the different 
forms of BC and the disease status, nanomaterials can be designed to reach the most forefront 
objectives of modern therapy and diagnosis. We here analyzed in details three main groups of 
nanomaterial applications for BC treatment and diagnosis. We have identified several types of drugs 
successfully conjugated with nanomaterials. We have analyzed the main important imaging 
techniques and all nanomaterials used to help non-invasive, early detection of the lesions. Moreover, 
we have examined theranostic nanomaterials as unique tools, combining imaging, detection, and 
therapy for BC. This state of the art provides a useful guide depicting how nanotechnology can be 
used to overcome current barriers in BC clinical practice, and how it will shape the future scenario of 
treatments, prevention, and diagnosis, revolutionizing the current approaches, i.e., reducing suffering 
related to chemotherapy. 
 
1. Introduction  
Breast cancer represents a malignant tumor where breast cells grow out of control and overcrowd 
normal cells. BC represents the most common type of cancer affecting women worldwide, and it is 
the second leading cause of death in the United States with 253 000 new cases estimated in 2017.1 
When BC occurs, it is crucial, for the prognosis, to get early detection, followed by opportune 
treatments including surgery and chemotherapy. Nowadays, the most important clinical analyses 
comprise mammogram, ultrasound exams, and nuclear magnetic resonance imaging (MRI). 
Moreover, biopsy and blood chemistry studies help for a more accurate diagnosis of BC. Around 4.9 
million breast biopsies are performed every year in the world, and 3.2 million of them are checked 
for screen detection of non-palpable breast lesions, of which a third is found to be malignant.2 
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However, by considering the current methods of BC diagnosis, any doctor can ensure a survival rate 
close to 100%. On the other hand, if we focus on BC therapy, many current treatments are invasive, 
involving several breast biopsies, wire-guided localization, and eventually surgical removal. All 
current treatments including chemotherapy and prophylactic strategies are disfiguring, invasive, and 
associated with significant side effects.3 
For all these reasons new diagnosis strategies and new effective and less toxic therapies are urgently 
needed. The recent advances in technology and engineering have led to the application of 
nanotechnology in medicine with the development of new nanoscale biomedical systems.4 
Nanomaterials have been explored for biomedical research because of their extraordinary 
physicochemical characteristics. In particular, cancer nanotechnology has proposed excellent 
approaches to cancer detection, diagnosis, and treatment with limited toxicity compared to the 
traditional cancer therapy.5 In this context, nanotechnology can create human-made materials in the 
nanoscale range, the same scale where cellular and biological processes take place.6 The major 
potential of cancer nanotechnology includes the possibility to engineer nanovehicles with multiple 
molecules that, because of their small size, can penetrate tumors with high specificity, consequently 
with significantly fewer side effects.7-9 Furthermore, techniques for nonsurgical ablation of tumors 
have been developed, leading to the complete destruction of tumor cells by the direct application of 
thermal and chemical therapies using nanomaterials, composed of metals, lipids, or polymers.10 
Therefore, cancer nanotechnology brings in the scenario of BC oncology huge expectations, and 
nanomaterials can be adapted the different BC forms and disease status. Because of the high degree 
of control, the characteristics of human-made nanotools can ensure new perspectives. Nanomaterials 
in BC can act as: i) drug nanocarriers, ii) nanodiagnostic tools, and iii) theranostic tools. 
Regarding drug delivery, nanomaterials can be designed to transport chemotherapeutic drugs directly 
to the breast cells using specific antibodies to target the cancer site.11 Doxorubicin (Dox) linked to 
nanomaterials is the most investigated drug for cancer therapy. Very recently the group of Ferrari has 
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described an injectable nanoparticle generator (iNPG), consisting of a discoidal micrometer-sized 
particle that can be loaded with Dox conjugated to poly(L-glutamic acid) (pDox).12 Intravenously 
injected iNPG-pDox accumulates into the tumor region and shows enhanced efficacy in mouse 
models of metastatic BC. 
In the context of the development of diagnostic tools, there are many successful examples of 
nanomaterials applied to visualize BC [i.e. superparamagnetic iron oxide nanoparticles (SPIONs) and 
magnetic nanoparticles (MNPs)]. Different studies have reported a sensitivity of 73-100% and a 
specificity of 92-98% in the lymph node using SPIONs.13 Among other advantages, SPIONs are 
useful for the early detection by MRI, displaying also a good immune-compatibility and echogenic 
properties.14 Today other nanotechnology-enabled systems are in clinical trials. For example, a [18F]-
FAC isodeoxycytidine analogue for deoxycytidine kinase (DCK) labeled with fluorine 18F, was 
proposed as a novel PET imaging probe.15 Nanoparticle MRI contrast agents that bind the αvβ3-
intregrin, expressed on the surface of the newly developing blood vessels associated with early tumor 
development, were developed.16 Lymphotrophic superparamagnetic nanoparticles developed by the 
MIT-Harvard Center for Cancer Nanotechnology Excellence were used to identify small, otherwise 
undetectable, lymph node metastases.16 
Before initiation of a cancer treatment, it is essential to carry out diagnostic imaging procedures to 
understand the type of cancer lesion. In this context, theranostic agents can combine diagnostic and 
therapeutic strategies into one procedure.17 Hosoya H. et al.18 described a hydrogel-based 
nanoplatform conjugated with Dox that enables ligand-directed tumor targeting and multimodal 
imaging. The data obtained using this strategy suggest that targeted hydrogel photothermal therapy 
represents a functional theranostic application such as image-guided approaches for diagnostic and 
therapeutic monitoring. Another revolutionary nanomaterial, graphene, and in particular graphene 
oxide (GO), has been studied for medical applications including tissue engineering, drug delivery, 
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and gene transfection; many studies have explained its potential as molecularly-targeted and dual-
modality imaging agent for in vivo imaging of BC.19 
In this Review, our purpose is to point out what are the most promising nanomaterials that can perform 
a breakthrough revolution in the scenario of BC. We provide a thorough overview of nanomaterials 
that have been so far investigated for the fight against BC, analyzing the most interesting publications 
present in the literature. We analyze the applications on drug delivery, imaging, and theranostics. We 
discuss all specific potentialities of the nanotechnology tools to overcome current barriers, to reduce 
toxicity, and to avoid suffering from anticancer treatments. This review aims to shed light on the 
challenges and hope offered by the different nanomaterials in the fight against BC. We propose a 
comprehensive analysis of the nanomaterials enrolled in this oncology context. 
 
2. Overview and studies selection criteria  
Initially, we have analyzed in details three main nanomaterial applications for BC: i) drug delivery, 
ii) imaging, and iii) theranostics. 
For this analysis, we performed a PubMed search using the following keywords: breast cancer, 
nanotechnology, nanomedicine, nanoparticles, nanomaterials, drug delivery, theranostics, and 
imaging. Keyword searching was also performed in different combinations. High impact review 
articles served as additional tools. The list of reported studies includes all retrieved publications from 
2009 to December 2017. In Table S1, S2 and S3 we show a full and deep characterization of all 
applications based ontype of materials, conjugated drugs, imaging modialities, applications other than 
imaging, model, type of species examined (human, mouse and their combination), other types of 
cancer other than BC. 
Figure 1 represents the number of publications over the years, the types of applications on therapy 
and diagnosis and the types of species examined in the cited works. The trend, from 2009 to December 
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2017, indicates an oscillating tendency in the studies on BC (Fig. 1A); i.e., the number of retrieved 
publications in 2011 was 1.5 higher compared to 2009. After a clear decrease in 2012, the state of 
publications in all the following years was higher than 2009. Imaging is the first application (58%), 
while 35% of the articles are referred to theranostic applications combined with drug delivery (Fig. 
1B). Besides, drug delivery, a single application, is reported in 7% of the works. In Fig. 1C we show 
the relative percentage of publications describing human cell lines (in vitro and ex vivo), mice (in 
vivo, vitro, and ex vivo), or both. Although there are no many differences regarding the percentage of 
publications of the examined species, we found that the majority of the studies has been carried out 
in humans cells (39%), 28% in mice, and 33% in both of them. International variations in BC 
incidence rates reflect differences in the availability of early detection tools as well as risk factors.20 
In this context, we analyzed the countries where BC studies were carried out, taking into consideration 
the affiliation of the corresponding author (Fig. S1). We found that the majority of the studies (39%) 
were conducted in USA, 26% in China, 5% in South Korea, 4% in Japan, Singapore and India, 3% 
in UK, 2% in Canada, Italy, Iran and Australia; a very few studies were conducted in other countries 
(< 2%). By the analysis of these percentages, we could conclude that there is no correlation between 
countries and incidence of BC. In fact, considering countries like United States where there is a high 
number of scientists, it is obvious to expect a larger amount of published works. A careful analysis 
of these data showed that there is not a strong correlation between the number of studies published 
and the relative incidence of BC. More developed countries represent about one-half of all BC cases 
with 38% of mortality. In fact, as reported in the pie graph (Fig. S1), USA, China, South Korea has 
got the highest percentage of studies compared to the other countries, but it was estimated that the 
higher mortality from BC occurs in Asian countries, as Qatar, India, and Iran. 
Since BC may lead to metastasis in other regions of human body, many scientists focused at the same 
time on other cancer forms together with BC. We found that many authors studied BC specific 
ligand/cell surface also identified in other type of cancers, or BC overexpressed receptors using other 
cancers as negative controls. Therefore, we report other types of cancer investigated with BC (Fig. 
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2). Lung cancer were studied in 22% of the papers, pancreatic and prostatic cancer in 19% of the 
papers, ovarian in 13%. Melanoma, colon and liver cancers were studied in 6% of the publications 
and the other types of cancer including gastric, glioblastoma and bone cancer resulted in3% of the 
cases (Fig. 2). 
 
3. Drug Delivery 
Drug delivery is a key nanotechnology application. In Table S1 we illustrate all publications on drug 
delivery in the context of BC. However, this type of application alone is reported in only the 7% of 
the cases considered. Indeed, in many examples, drug delivery applications refer to theranostic 
applications (corresponding to 35% of the studies). Analyzing the different publications, we found 
several types of drugs used in drug delivery or in combination leading to theranostic nanomaterials 
(Fig. 3). These drugs comprise Dox, herceptin, paclitaxel (PTX), dextran, curcumin, mitoxantrone, 
tamoxifen, methotrexate, pentoxifylline, and docetaxel. Dox represents the most important anticancer 
chemotherapeutic drug.21 Indeed, its ability to intercalate DNA bases, inhibiting the topoisomerase II 
enzyme during DNA transcription was widely demonstrated.22 Many studies used nanomaterials 
conjugated with Dox as an innovative cancer therapy.22-27 Herceptin was used for the treatment of 
metastatic BC, thanks to its properties of blocking cells proliferation.28-33 Recently, Wang et al.34 
reported a synthesis of a particular multifunctional anti-cancer complex based on functionalized 
magnetic nanoparticles (MNPs) and quantum dots (QDs) with a dual-drug combination. In detail, the 
PTX/MNPs/QDs@Biotin–PEG–PCDA nanoparticles nanoparticles have shown a high uptake by BC 
cells (MCF-7/ADR) and good drug release. These nanoparticles are able to combine various 
proprieties useful for imaging (QDs), targeted delivery and uptake (MNPs), and dual drug treatment 
using two drugs (i.e., PTX and curcumin). Curcumin, a natural compound extracted from curcuma 
longa, helped to obtain a high PTX accumulation in the tumor target and induces a down-regulation 
of drug efflux transporters. Moreover, PTX has shown excellent efficacy in a wide spectrum of cancer 
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treatments, but its formulation has led to serious side effects in patients, as neurotoxicity, 
nephrotoxicity and allergic reaction. Modified PTX as nanomicelles was developed to overcome these 
obstacles and multidrug resistance.35 
Zhao et al.36 described hybrid paclitaxel nanocrystals that integrated fluorescent molecules for 
therapeutic and imaging in a breast tumor. The authors observed a more efficient anticancer effect of 
this system in mice with breast tumor than in mice treated with pure PTX. The hybrid PTX 
nanocrystals have shown the ability to easily accumulate in the tumor area following intravenous 
administration. Others described PTX release directly into the tumor sites for theranostic 
nanomedicine application 34-37 and drug delivery.38 In the third position of the most important drugs 
used in the cancer fight, we found curcumin, a compound endowed of interesting properties including 
an anti-inflammatory action.39 Curcumin can specifically modulate the expression of proteins in 
proliferating cells, in adhesion and in migration, and it is used as an anticancer drug to prevent 
metastatic formation or to limit cancer progression.40,41  
Furthermore, other types of drugs such as dextran33, 42, 43 or docetaxel44, 45 were loaded into 
nanoparticles for cancer detection, while mitoxantrone,46 tamoxifen,47 methotrexate,48 
pentoxifylline,49 docetaxel,50, 51 cisplatin and gemcitabine were combined for the development of 
theranostics materials.52 Recently, the group of Chan provided quantification of the delivery 
efficiency of nanoparticles at the tumor site. They reported a bombshell work whose meta-analysis 
suggested that very few "targeted" nanoparticles reach the target. According to this analysis, only 7 




Nowadays, nanotechnology based on imaging represents a very promising solution for non-invasive 
investigations of cancer lesions. We found that in 58% of the examined studies the first approach 
against BC is based on the use of nanotools for imaging (Fig. 1B). Breast imaging can be undertaken 
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using MRI, the most commonly available modality, thanks to its rapidity and high resolution (Fig. 
4A).54 Different nanoparticles with appropriate surface modification have been used in vivo as MRI 
contrast agents because of their high magnetization and nano-size.55 In particular, the surface coating 
was exploited to create non-toxic and biocompatible nanomaterials (see Table S2).56-78 For example, 
Medarova et al.79 have modified SPIONs with Cy5.5 dye and conjugated them to specific peptides. 
This tumor-specific contrast agent was able to successfully target the under-glycosylated MUC-1 
(uMUC-1) tumor antigen, present in over 90% cases of BCs. 
MRI is followed by two other techniques, namely fluorescence imaging (FI)5, 64, 78, 80-119 and confocal 
laser scanning microscopy (CLSM) (Fig. 4A).58, 64, 67, 73-75, 120-134 Both of them have shown to be 
excellent imaging tools for many in vitro studies on murine and human cancer cells. 
Pan et al.120 described in vitro cancer detection of human cells (MCF-7) using fluorescent quantum 
dots (QDs) as luminescent probes for targeted imaging. The authors described a new strategy to 
prepare QDs formulated in folate-decorated nanoparticles (PLA-TPGS/TPGS-COOH) (PLA-TPGS, 
poly(lactide)-D-α-tocopheryl polyethylene glycol succinate) for BC detection and diagnosis at its 
early stage. They demonstrated that functionalization with a copolymer was able to improve imaging 
sensitivity with reduced side effects on normal cells. Another imaging technique used in BC studies 
is the near-infrared (NIR) optical imaging, 56, 79, 83, 96, 97, 99, 107, 112, 127, 132, 135-143 which represents the 
fourth most exploited type of modality in the total of the examined studies. Through NIR fluorescence 
images, the authors analyzed directly in vivo the biodistribution of many nanomaterials in different 
organs and their elimination. Bardhan et al.56 used modified gold nanoshells (AuNSs) with 
fluorophores to enhance the fluorescence in live mice grafted with human cancer cell lines over 72 h. 
The nanocomplex, conjugated with specific antibodies to target human epidermal growth factor 
receptor 2 (HER2) overexpressed in BC, provided significant information regarding the distribution 
of nanomaterial, and represents a new approach for cancer therapy and non-invasive treatment for 
soft-tissue tumors.56 
Moreover, we found that computed tomography (CT)70, 113, 139, 144-152 is at the fifth position in terms 
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of number of works related to BC, while other techniques are less used, including superconducting 
quantum interference device (SQUID),94, 153 surface enhanced Raman scattering (SERS),81, 154-159 
synchrotron X-ray micro-imaging (X-ray),150, 152, 160, 161 positron emission tomography (PET),106, 115, 
142, 162 and fluorescence molecular tomography (FMT).70, 73 We reported that single-photon emission 
computed tomography (SPECT),163 ultrasound imaging (US),71 intermolecular quantum coherence 
(iMQC),164 optical coherence tomography (OCT),165 ultrashort echo time (UTE)166 are in the last 
positions as imaging techniques used (Fig. 4A). Focusing on the imaging tools, we found that the first 
most studied nanomaterials are SPIONs (Fig. 4B).  
Many publications have shown the interesting potential of SPIONs for tumor detection, cancer 
therapy and drug delivery.13, 54, 57, 59, 61, 64, 67, 68, 74-79, 94, 100, 104, 145, 148, 164, 166-170 SPIONs are applied as 
molecular imaging probes due to their monodisperse size distribution, but for biomedical 
applications, a surface modification [i.e., with poly(2-hydroxyethyl aspartamide)] is necessary to 
make them stable under physiological conditions and to avoid the uptake by phagocytic cells.57 A 
recent publication has shown their use for gene therapy. Lin et al.74 discovered that SPIONs 
conjugated with small interfering RNA (siRNA) were able to silence the target messenger RNA, 
consequently reducing the expression of P-glycoprotein (P-gp), a cell membrane protein responsible 
of multidrug resistance. Through this gene therapy, the authors demonstrated an excellent down-
regulation of P-gp in MCF-7/ADR human BC cell lines in orthotopic mouse model. 
In the same way of SPIONs, other small size (5-8 nm) magnetic nanoparticles (MNPs) have also 
shown the same characteristics in terms of,58, 69, 70, 72, 73, 83, 102, 125, 126, 131, 134, 139, 153, 171 biodistribution, 
and ability to carry more compounds thanks to their high surface availability. In this context, Yigit et 
al.171 used MNPs linked to microRNA (miRNA) for gene therapy. The treatment of human BC cells 
(MDA-MB-231) in vitro and in vivo with the nanocomplex down-regulated a pro-metastatic 
microRNA (miR-10b) arresting the metastatic process, thus preventing the formation of lymph node 
metastases. Regarding QDs, we found that they are in the third position as nanomaterials for imaging. 
Thanks to their fluorescence properties upon excitation, their high brightness and photostability, they 
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represent unique nanomaterials ideal for in vivo imaging in animal cancer models, as shown in the 
measurement of the receptor expression level of type I insulin-like growth factor receptor (IGFIR) 
involved in BC proliferation and metastasis.122 QDs have been coated with polymer to enhance 
biocompatibility,64, 89, 92, 95, 101, 114, 120, 133, 172 or conjugated with antibodies to detect overexpressed 
receptors.85, 88, 90, 91, 98, 99, 107-110, 116, 122, 135 
The fourth position is held by gold nanoparticles, used for tumor detection, diagnosis, and cancer 
therapy, due to the possibility of an easy surface modification.173 The advantages of these 
nanomaterials include non-cytotoxicity, chemical stability, and high affinities for biomolecules.121 
Indeed, they can scatter visible and near-infrared light through surface plasmon resonance, so that 
they have been used in many microscopic techniques including CLSM,121, 130, 174 CT,113, 147, 149, 150, 152 
FI,5, 87, 103, 113 and other imaging techniques like X-ray,150, 152, 160 NIR imaging141 and SERS.155, 175 
Finally, other imaging nanomaterials (Fig. 4B) such as poly(lactic-co-glycolic) acid nanoparticles 
(PLGA),71, 80, 97, 176 mesoporous silica nanoparticles (MSNs),75, 86, 140, 142 liposomes,93, 100, 144, 146, 177, 178 
silica- AuNSs,56, 137, 154, 165 gold nanorods (GNRs),78, 84 carbon nanotubes (CNTs),82, 129 nanoglobules 
62, 66, graphene oxide,115, 163 and nanodiamonds (NDs)179 have been studied for breast tissue imaging 
and cancer therapy (see Table S2). 
 
5. Theranostics 
Recently, nanotechnology has provided new strategies that combine therapy and diagnosis 
approaches. The introduction of the word “theranostics” represents a well-established field of 
nanotechnology where multifunctional materials can be used for the detection and treatment of cancer 
disease in a single procedure. Of particular importance is the simultaneous combination of contrast 
agents and therapeutic functions using chemically-modified nanoparticles or fluorescent probes.180, 
181 In Table S3 we report a characterisation of all theranostic applications found in the literature for 
BC. Regarding nanoparticles, we found MNPs in the first position in terms of theranostic materials 
investigated, followed by calcium phosphosilicate composite nanoparticles (CPSNPs), liposomes, 
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AuNPs and GNRs, AuNSs, CNTs and polymers (Fig. 5). Theranostic MNPs have demonstrated 
excellent performances in tumor detection,182-185 drug delivery,184, 185 and cancer therapy in mice 
model studies.186, 187 Part of the works examined were carried out in vitro on MDA-MB-231,40, 41 
MCF-7,41, 47, 188, 189 H1299 human cell lines,188 as preliminary studies to evaluate the response to 
cancer therapy. Basuki et al.188 described the theranostic application of MNPs loaded with polymers 
and Dox in in vitro experiments using MCF-7 on H1299 human cell lines. The authors demonstrated 
accumulation of MNP-Dox in lung and BC cell lines through MRI and Dox release to cancer cells 
using CLSM and FI techniques. For theranostic, GNPs, AuNSs have raised interest in photodynamic 
therapy,190, 191 photothermal therapy,180, 192-194 ultrasonography192 and gene therapy.180 On the other 
hand, in the context of imaging, AuNPs have shown main applications regarding tumor detection.18, 
29, 195-200 
In the third position we found other known theranostic materials such as MSNs used for tumor 
targeting and drug delivery,30, 201-203 GNRs for tumor detection and drug delivery,31, 32, 204 gene 
therapy,205 and photothermal therapy.206, 207 We also found liposomes for tumor detection and drug 
delivery,46, 50, 208, 209 and other new theranostics systems like CNTs48, 210-213 and CPSNPs.214, 215 In 
particular, we have shown that CNTs have good echogenic properties like contrast agents, with a 
promising future in the field of theranostic applications.216 Even though positioned in the fourth 
position, QDs have acquired more importance in the field of theranostic applications. Rizvi et al.217 
reported an in vitro experiment using QDs loaded with antibodies for HER-2 localization in fixed and 
live cells (SK-BR-3 and MCF-7 cells). This study underlines how QDs coated with 
mercaptoundecanoic acid appeared non-toxic up to 24 h of exposure, and an excellent in vitro imaging 
agent. For this reason, QDs can be potentially used for targeted therapy in image-guided surgery and 
cancer therapy to directly destroy tumor cells. In addition to traditional nanomaterials, the 
combination of polymeric materials has opened a new way for theranostic nanomaterials, known as 
nano-complexes (Fig. 5). Their properties have allowed a controlled release of drugs in addition to 
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many medical applications, like photoacoustic tomography,218 photothermal therapy,219-221 
photodynamic therapy,222 drug delivery37, 49, 223-229 and cancer therapy.230-234 
During the last years, graphene-based materials have been investigated in biomedical applications 
thanks to its unique intrinsic chemical and physical properties.235 Excellent electrical conductivity, 
ideal photothermal response, large surface area, and versatile chemistry have stimulated the 
researchers to explore graphene based materials for applications in tissue engineering, drug delivery, 
molecular imaging and others. For example, Shi et al.236 reported reduced GO (rGO) as an excellent 
photothermal agent that enabled in vivo tumor ablation. rGO could be also used as theranostic 
materials to integrate imaging and therapeutic components to fight cancer.236 Recent researches of 
nanotechnology based on other carbon nanomaterials as NDs, CNTs, and fullerenes have provided 
good results about their possibility to become theranostic agents in the different field of nanomedicine 
such as drug delivery, regenerative medicine, bioimaging. Carbon nano-onions (CNOs) showed the 
same vectorization characteristics possessed by CNTs, as we described in a previous work.237 
Recently Bartelmess et al.238 demonstrated a simple cell-penetration capability of CNOs in an in vitro 
MCF-7 human BC cell line. Boron dipyrromethene (BODIPY) functionalized CNOs exhibited high 
fluorescence intensity for high-resolution imaging and did not show significant toxicity effects. These 
results make modified CNOs as new theranostic materials able to combine imaging, targeting and 
therapeutic modalities. 
 
6. Conclusions and future views  
We here reported a thorough and detailed review on nanoscale innovations against BC proposed in 
the last nine years. We have evidenced an increasing interest in the study of nanotechnological 
applications to BC. Nanotechnology offers a possibility for early breast lesion detection and search 
for more efficient therapies to significantly impact the degree of mortality of BC patients. Despite 
numerous studies on the application of nanotechnology in medicine, the hypothetical benefits still 
need to be clarified. Most of the nanomaterials tested have not been able to provide high efficiency 
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for clinical use. Considering the intrinsic physicochemical properties of nanomaterials and all works 
analyzed here, superparamagnetic iron oxide nanoparticles, quantum dots, graphene and liposomes 
represent the best choice as advanced drug carriers for BC therapy. On the other hand, gold silica 
nanoparticles, nanoshells, nanorods, nanocages, and nanotubes were especially studied as 
photothermal agents under radiofrequency or magnetic field activation in non-invasive imaging and 
cancer therapy.239 Regarding drug delivery, nanoparticles have been engineered as drug vehicles to 
bring drug directly at the tumor site, to reduce toxic side effects of antineoplastic agents, and to 
enhance combinatorial drug delivery. Among all reported studies we highlighted the most promising 
ones. Recent studies focused on new strategies based on a combination therapy through a co-
administration of multiple drugs using a single treatment. For example, this approach was carried out 
by Murugan et al.240 to describe nanocarrier mediated inhibitory effects of topotecan and quercetin 
on BC cells like a new targeted therapeutic strategy to treat cancer. These revolutionary nanocarries 
have shown an excellent intracellular release of loaded drugs with important molecularl-induced 
modifications leading to structural charges in endoplasmatic reticulum, nucleus and mitochondria in 
tumor cells.240 
Nanotechnology can offer potential nanomaterials for creating new methods for detection, targeting 
and killing BC at different stages. Several authors reported the problematic use of many nanomaterials 
because of their non-specific toxic effects in in vivo animal models. One of the major advantages of 
using nanoparticles are based on the possibility to modify their characteristics to face physical and 
biological barriers after injection. However, the analysis of the recent publications disclosed that the 
delivery efficiency has not advanced during the last ten years.  
Regarding innovative approaches able to accelerate the nanotool integration into the clinic, we would 
like to mention single cell techniques and in particular single cell mass cytometry. We recently 
described how this approach could reveal the effect of graphene and nanomaterials in general on 
immune cells.241 Being aware that single cell mass cytometry can be useful in the context of BC, as 
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proven recently by the group of Bodenmiller, 242, we believe it will be of interest to apply this 
approach on nanotools to validate their effect on BC treatment. 
In conclusion, despite the numerous studies found in the literature, only a few nanomaterials or nano-
compounds will move on from the pre-clinical phase and will be selected for clinical trials. Indeed, 
the research on biocompatibility are still at the early stage. Given the great interest reported in recent 
years, graphene could be one of the promising nanomaterial to fight BC. Moreover, at present, the 
possibility to control the nanoparticles transport and the real delivery efficiency in the body for cancer 
treatment remains the real challenge for nanotechnology-based tools against BC. 
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Fig. 1. Status of applications used on BC studies. A) Analysis of publications in the last 9 years (2009 
to 2017). B) Relative percentages of publications for imaging, theranostic and drug delivery 








Fig. 3. Conjugated drugs to nanomaterials. Number publications in the last 9 years based on the type 
of drugs conjugated to nanomaterials and nanoparticles to fight BC. 
 
 
Fig. 4. Overview on different types of techniques and nanomaterials for imaging. A) Analysis of the 
number of publications based on the different kind of Imaging Applications for BC.  B) Types of 
nanomaterials used for imaging. 
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GNRs =  Gold Nanorods
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Nanoparticles
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How can nanotechnology help the fight against breast cancer? 
 










Fig. S1.  Percentage of publications carried out on nanomaterials fight against BC per Countries. The 
piece of the cake in yellow, reported the studies in a percentage of <2 % conducted in other countries 
such as: New Zealand, Greece, Brazil, Taiwan, Malaysia, Riyadh-Saudi Arabia, The Netherlands, 









Table S1: Drug delivery 
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* The reference numbers in the table refer to those in the main text. 
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(64Cu-NOTA-GO-
FSHR-mAb) 
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Fluorescence 
images 
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SERS 




































free (bio CFQD®) 
CLSM 






















Magnetic Nanowires Antibody FI 
In vitro / Ex vivo 
(MCF-7, MDA-
MB-231 cells)  
[119] 
Gold Nanostars Antibody SERS 



































SERS Nanoparticles ─ SERS 
In vitro 
(SKBR3, MDA-
MB-231 cells)  
[159] 
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Model Cell type Ref.* 
Magnetic 
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(MGITC, Rh6G, Cy5) 
Tumor 
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TNBC cells)  
[230] 
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Ex vivo 



















(MCF7 cells)  
 
[202] 
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In vitro / In vivo 


















In vitro / In vivo 
(4T1 cells)  
[209] 
* The reference numbers in the table refer to those in the main text. 
 
